Agilent Technologies announced a change in its organizational structure to enhance its market-focused, customer-centric strategy. The company has reorganized its business into three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.

The Life Sciences and Diagnostics Markets segment now includes the former Diagnostics and Genomics segment along with the liquid chromatography and liquid chromatography mass spectrometry instrument platforms. The Agilent CrossLab segment now incorporates chemistries and supplies, laboratory automation, and software and informatics divisions, which were previously part of the Life Sciences and Applied Markets segment. The remaining divisions from the former Life Sciences and Applied Markets segment, including gas chromatography, gas chromatography mass spectrometry, remarketed instruments, spectroscopy, and vacuum divisions, now form the new Applied Markets segment.

To reflect these structural changes, Agilent has recast certain sections of its Annual Report on Form 10-K for the year ended October 31, 2024, including sections on Business, Properties, Management’s Discussion and Analysis of Financial Condition and Results of Operations, and Financial Statements and Supplementary Data. However, this recast does not amend or restate the audited consolidated financial statements but serves for informational purposes only.

The company advises investors to refer to its most recent filings, including the Quarterly Report on Form 10-Q for the period ending January 31, 2025, for updated financial and operational information.